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Abstract
Background: Malignant optic gliomas are rare, but they rapidly become lethal visual pathway tumors. We present
the clinical course, treatment, and prognosis of a case of unilateral malignant optic glioma in a young man with a
history of brain glioblastoma multiforme (GBM).
Case presentation: A 21-year-old man, who had GBM 7 years ago complained of a transient shadow in his vision
and presented with normal visual acuity but optic disc edema and an enlarged blind spot in the right eye (oculus
dexter, OD). Magnetic resonance imaging (MRI) showed a right intraorbital optic nerve tumor without a brain
lesion. Chiasm involvement and severe vision deterioration occurred 3 months later. A biopsy of the right optic
nerve revealed glioblastoma. Concurrent chemoradiotherapy (CCRT) prevented involvement of the fellow eye
1 year after symptom onset.
Conclusion: This report demonstrated that a regular ocular exam should be recommended for several years after
GBM. In young healthy patients who are able to undergo chemotherapy and radiotherapy, visual function in the
fellow eye can be preserved.
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Background
Glioblastoma multiforme (GBM) is the most frequent and
lethal type of malignant primary brain tumor in humans,
and it has the poorest prognosis with a median survival of
generally < 1 year from the time of diagnosis [1–3]. GBM
is rarely observed in children, which comprising only
5–10% of childhood intracranial neoplasms [4].
Malignant optic glioma is rare and was first defined by
Hoyt et al. in 1973 [5]. It is a high grade astrocytoma,
presenting as an anaplastic astrocytoma (AA) (WHO
grade III) or glioblastoma (WHO grade IV) [6]. Patients
frequently have bilateral visual loss within a few weeks
and die within 1–2 years [7, 8]. Here, we report a young
man presenting with unilateral malignant optic glioma
after having GBM for >5 years.
Case presentation
The 21-year old man was diagnosed with brain GBM
at 13 years of age (Fig. 2a, b). After tumor extirpa-
tion, he regularly underwent temozolomide chemo-
therapy and radiotherapy (66.6 Gy) from February
2007 to April 2007 and no brain GBM recurrence
was shown at brain MRI during this round of treat-
ment. However, progressing in cystic size was noted
during regular clinics visit after previous treatment,
radical resection of tumor was done in August 2007.
Then he maintained with Temozolomide treatment
for 8 more years (111 cycles). In August 2015, he
visited our clinic complaining of an intermittent
shadow in his vision when changing positions (dur-
ation 1–2 min/attack, >5 times/day) for several years.
The best-corrected visual acuity (BCVA) was 20/20 in
both eyes. Ocular examinations revealed a right
relative afferent pupillary defect (RAPD) and optic
disc swelling (OD; Fig. 1a). Visual field (VF) testing with a
Humphrey automated perimeter (Swedish Interactive
Threshold Algorithm, SITA) revealed an enlarged blind
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spot (OD; Fig. 1c). Optical coherence tomography showed
severe optic disc head swelling and normal central
macular thickness. The patient received intravenous
methylprednisolone for 3 days for suspected optic
neuritis (OD). Orbital MRI revealed a pre-chiasmatic
enhanced fusiform optic nerve tumor on a T1-
weighted contrast image, typical of optic nerve glioma
(Modified Dodge classification : 1aR) [9] (Fig. 2e, f ). No
tumor recurrence was found in brain MRI (Fig. 2d).
Cerebrospinal fluid (CSF) examination revealed no defin-
ite malignant cells. Based on the diagnosis of an optic
nerve tumor, likely secondary to GBM, aggressive chemo-
therapy (temozolomide 380 mg) was administered. Three
months later, BCVA (OD) deteriorated to 20/30 and the
VF was severely constricted with only central area preser-
vation (Fig. 1d). A follow-up orbital MRI showed progres-
sive changes in the right optic nerve lesion involving the
chiasm on a T1- weighted image (Modified Dodge classifi-
cation : 2cR) [9] (Fig. 2h, i). One month later, BCVA (OD)
worsened to 2/200. Histopathology from a right optic
nerve biopsy revealed glioblastoma. One month after the
biopsy, the patient received combined concurrent chemo-
radiotherapy (CCRT) with temozolomide (140 mg/day)
and irradiation of the involved field (60 Gy, 30 times).
Afterwards, a new regimen of chemotherapy was adminis-
tered (Bevacizumab) and he reported no light perception
(OD). The complete clinical course is presented as time
table (Table 1).
However, at 11 months after symptom onset, brain
MRI showed a right optic nerve tumor extending to the
optic chiasm with progression in size (Modified Dodge
classification : 2b R/L) [9] (Fig. 2k, l). He underwent a
right optic nerve tumor resection.
One year after symptom onset, BCVA and VF were
within the normal range in the left eye (oculus sinister,
OS) and no recurrence or metastasis was noted in the
latest follow-up brain MRI.
Discussion and Conclusions
GBM is a highly malignant brain tumor with a poor
prognosis. GBM constitutes approximately 17 and 6.5%
of intracranial neoplasms in adult and pediatric popula-
tions, respectively [10, 11].
Currently, standard care to improve GBM patient
survival begins with surgical removal followed by radiation
and chemotherapy [2]. Despite optimal treatment, most
patients die of the disease, and the median overall survival
time is 12–15 months [1, 12]. The main parameters asso-
ciated with long-term survival are younger age (<40 years),
good performance status, and the ability to undergo gross
total resection, followed by radiotherapy and chemother-
apy [2, 10, 13]. GBM can easily metastasize within the
neuroaxis (i.e., the meninges or spinal cord) via the CSF
occurring in approximately 20% of GBM patients [14].
GBM metastases outside the central nervous system are
rare [15], but may be found in the extraocular muscles,
Fig. 1 Fundus imaging showed (a) a swollen optic disc in the right eye, (b) a normal optic disc in the left eye. Humphrey automated perimetry
(SITA) revealed (c) an enlarged blind spot in the right eye at the initial symptom onset and (d) severe constriction with only central area
preservation in the right eye 3 months after symptom onset
Lin and Huang BMC Ophthalmology  (2017) 17:21 Page 2 of 5
limbus, or orbit [16, 17]. Systemic chemotherapy is the
only treatment that considerably prolongs overall survival
times [12], which seem not to differ regardless of GBM
developing extracranial metastasis.
The most common tumor of the optic nerve is optic
nerve glioma, which represents approximately 66% of all
primary optic nerve tumors. Approximately 90% of optic
gliomas occur in children and most cases are relatively
benign [18]. Malignant optic gliomas are rare, and
mostly present in middle aged men [19]. From 1900 to
2015, only 22 cases of pathology proven optic nerve
glioblastomas were recorded among 66 cases of primary
malignant optic gliomas [7, 8]. At onset, 70% patients
with malignant optic nerve gliomas present with symptoms
Fig. 2 T1 weighted contrast – enhanced MRI showed (a, b) original right frontoparietal glioblastoma (c) without right optic nerve involvement.
At the initial symptom onset, T1 weighted contrast – enhanced MRI with fat suppression showed (d) no evidence of brain tumor recurrence but
(e, f) right pre-chaismatic enhanced fusiform optic nerve tumor. At 3 months after symptom onset, T1 weighted contrast – enhanced MRI with
fat suppression showed (h, i) right fusiform enlargement and an enhanced optic nerve tumor intraorbitally extending towards the optic chiasm
even (g) no brain tumor recurrence. At 11 months after symptom onset, T1 weighted contrast – enhanced MRI with fat suppression showed
(k, l) right optic nerve tumor extending to the optic chiasm and progressing in size (j) without brain tumor recurrence
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of acute unilateral visual loss, spreading rapidly over the
chiasm and leading to total blindness typically within
3 months [8].
Neuroradiologic findings are unspecific and typically
described as contrast enhancement and thickening of
the optic nerve, chiasm, or tract, with lesions having
hypo- to iso-intensity on T1-weighted images [20]. Biop-
sies continue to be necessary to confirm a diagnosis [7].
The current standard therapy consists of surgical re-
section or biopsy as feasible, followed by radiotherapy
and/or temozolomide chemotherapy for high grade as-
trocytomas [7, 21]. The prognosis of a malignant optic
glioma is fatal and most patients die within 1 year [7, 8].
Our case was challenging; diagnosis was difficult be-
fore biopsy because the optic nerve tumor appeared
7 years after brain GBM and visual function was initially
normal. In addition, the complications of radiotherapy
were a concern. The relationship between delayed radio-
therapy and the progression and extension of the optic
nerve tumor was unclear. Fortunately, BCVA and VF in
the fellow eye remained unchanged despite the chiasm be-
coming involved 1 year after the symptom onset. Com-
pared with previous reports, the progression of the optic
malignant tumor was slower and the prognosis was better.
In summary, malignant optic tumors may appear >5 years
after brain GBM. Regular ophthalmic examinations and
brain MRIs are recommended for early diagnosis. Add-
itional studies should evaluate the role and optimal timing
of early adjuvant radiotherapy before visual function de-
creases. Young age, good health, and the ability to undergo
CCRT can palliate the clinical course and preserve visual
function in the fellow eye.
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